The 3,4-dihydro-2(1H)-quinolinone moiety is present in a number of pharmacologically active compounds. These include FDA approved drugs such as cilostazol, carteolol and aripiprazole as well as numerous experimental compounds. Compounds containing the 3,4-dihydro-2(1H)-quinolinone moiety also exhibit a variety of activities in both the peripheral and central tissues, which includes phosphodiesterase inhibition, blocking of β-adrenergic receptors, antagonism of vasopressin receptors and interaction with serotonin and dopamine receptors. Based on its versatility in drug design and action, this paper reviews the pharmacological actions of compounds containing the 3,4-dihydro-2(1H)- quinolinone scaffold with emphasis being placed on the most important and significant members of each activity class.

中文翻译：

---

3，4-二氢-2（1H）-喹啉酮的药理特性综述。

3，4-二氢-2（1H）-喹啉酮部分存在于许多药理活性化合物中。这些包括FDA批准的药物，例如西洛他唑，卡替洛尔和阿立哌唑，以及许多实验性化合物。含有3,4-二氢-2（1H）-喹啉酮部分的化合物在外周组织和中枢组织中也表现出多种活性，包括磷酸二酯酶抑制，β-肾上腺素能受体的阻断，血管加压素受体的拮抗作用以及与血清素的相互作用。和多巴胺受体。基于其在药物设计和作用上的多功能性，本文综述了含有3,4-二氢-2（1H）-喹啉酮骨架的化合物的药理作用，重点放在每种活性类别中最重要和最重要的成员上。